Patents by Inventor George Wilding

George Wilding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR IMPROVING YIELD CHARACTERISTICS IN PLANTS
    Publication number: 20240090466
    Abstract: This invention relates to compositions and methods for modifying homeodomain-leucine zipper transcription factor (HD-Zip) genes in plants. The invention further relates to plants having improved yield characteristics produced using the methods and compositions of the invention.
    Type: Application
    Filed: September 7, 2023
    Publication date: March 21, 2024
    Inventors: Brian Charles Wilding Crawford, Lolita George Mathew
  • Chroman-derived anti-androgens for treatment of androgen mediated disorders
    Patent number: 9440942
    Abstract: Methods for the prevention and/or alleviation of androgen-mediated disorders treatable by administering a chroman-derived anti-androgen compound are provided by the present invention. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived anti-androgen compounds useful in the prevention and/or alleviation of androgen-mediated disorders, particularly prostate cancer.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: September 13, 2016
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Todd A. Thompson, George Wilding
  • Androgen induced oxidative stress inhibitors
    Patent number: 9023837
    Abstract: Described herein are pharmaceutical compositions and medicaments, and methods of using such pharmaceutical compositions and medicaments in the treatment of cancer.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: May 5, 2015
    Assignee: Colby Pharmaceutical Company
    Inventors: Hirak S. Basu, David A. Zarling, George Wilding, Farideh Mehraein-Ghomi, Dawn R. Church
  • CHROMAN-DERIVED ANTI-ANDROGENS FOR TREATMENT OF ANDROGEN MEDIATED DISORDERS
    Publication number: 20140323560
    Abstract: Methods for the prevention and/or alleviation of androgen-mediated disorders treatable by administering a chroman-derived anti-androgen compound are provided by the present invention. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived anti-androgen compounds useful in the prevention and/or alleviation of androgen-mediated disorders, particularly prostate cancer.
    Type: Application
    Filed: July 10, 2014
    Publication date: October 30, 2014
    Inventors: Todd A. Thompson, George Wilding
  • Chroman-derived anti-androgens for treatment of androgen mediated disorders
    Patent number: 8809387
    Abstract: Methods for the prevention and/or alleviation of androgen-mediated disorders treatable by administering a chroman-derived anti-androgen compound are provided by the present invention. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived anti-androgen compounds useful in the prevention and/or alleviation of androgen-mediated disorders, particularly prostate cancer.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: August 19, 2014
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Todd A. Thompson, George Wilding
  • N1,N4-BIS(BUTA-1,3-DIENYL)BUTANE-1,4-DIAMINE PHARMACEUTICAL COMPOSITIONS AND METHODS THEREOF
    Publication number: 20140179798
    Abstract: N1,N4-bis(buta-1,3-dienyl)butane-1,4-diamine dihydrochloride (also referred to as MDL 72,527 and N,N?-di-2,3-butadienyl-1,4-butanediamine dihydrochloride), or salts or solvates thereof, its use as an antioxidant, its use in preventing and/or treating prostate cancer in male humans, and its use in reducing the concentration of reactive oxygen species in human prostate gland tissue or any other body tissue, and methods of making the compound thereof are disclosed. Other disclosed methods include inhibiting acetyl polyamine oxidase in human prostate tissue or other human body tissue comprising administering a therapeutic amount of N,N?-bis(2,3-butadienyl)-1,4-butanediamine or a salt or solvate thereof to the human, and a method of determining oxidative stress in human prostate tissue or other human or animal body tissue comprising measuring a ratio of oxidized 2?,7?-dichlorodihydrofluorescein diacetate fluorescence:DNA fluorescence and hydroethidine dye fluorescence ex vivo or in vivo.
    Type: Application
    Filed: February 28, 2014
    Publication date: June 26, 2014
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Hirak S. Basu, Dawn R. Church, Patrick M. Woster, George Wilding
  • CHROMAN-DERIVED ANTI-ANDROGENS FOR TREATMENT OF ANDROGEN MEDIATED DISORDERS
    Publication number: 20140045929
    Abstract: Methods for the prevention and/or alleviation of androgen-mediated disorders treatable by administering a chroman-derived anti-androgen compound are provided by the present invention. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived anti-androgen compounds useful in the prevention and/or alleviation of androgen-mediated disorders, particularly prostate cancer.
    Type: Application
    Filed: August 14, 2013
    Publication date: February 13, 2014
    Applicant: Wisconsin Alumni Research Corporation
    Inventors: Todd A. Thompson, George Wilding
  • Chroman-derived anti-androgens for treatment of androgen mediated disorders
    Patent number: 8536219
    Abstract: Methods for the prevention and/or alleviation of androgen-mediated disorders treatable by administering a chroman-derived anti-androgen compound are provided by the present invention. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived anti-androgen compounds useful in the prevention and/or alleviation of androgen-mediated disorders, particularly prostate cancer.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: September 17, 2013
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Todd A. Thompson, George Wilding
  • ANDROGEN INDUCED OXIDATIVE STRESS INHIBITORS
    Publication number: 20130210772
    Abstract: Described herein are pharmaceutical compositions and medicaments, and methods of using such pharmaceutical compositions and medicaments in the treatment of cancer.
    Type: Application
    Filed: April 15, 2011
    Publication date: August 15, 2013
    Applicant: COLBY PHARMACEUTICAL COMPANY
    Inventors: Hirak S. Basu, David A. Zarling, George Wilding, Farideh Mehraein-Ghomi, Dawn R. Church
  • CHROMAN-DERIVED ANTI-ANDROGENS FOR TREATMENT OF ANDROGEN MEDIATED DISORDERS
    Publication number: 20120277301
    Abstract: Methods for the prevention and/or alleviation of androgen-mediated disorders treatable by administering a chroman-derived anti-androgen compound are provided by the present invention. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived anti-androgen compounds useful in the prevention and/or alleviation of androgen-mediated disorders, particularly prostate cancer.
    Type: Application
    Filed: July 5, 2012
    Publication date: November 1, 2012
    Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Todd A. Thompson, George Wilding
  • Chroman-derived compounds for the treatment of cancer
    Patent number: 7863324
    Abstract: The present invention provides methods for inhibiting the growth of androgen-independent prostate cancer tumor cells in a human comprising administering to the human. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived compounds useful in the alleviation of cancer.
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: January 4, 2011
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Todd A. Thompson, George Wilding
  • Chroman-derived anti-androgens for treatment of androgen-mediated disorders
    Patent number: 7709525
    Abstract: Methods for the prevention and/or alleviation of androgen-mediated disorders treatable by administering a chroman-derived anti-androgen compound are provided by the present invention. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived anti-androgen compounds useful in the prevention and/or alleviation of androgen-mediated disorders, particularly prostate cancer.
    Type: Grant
    Filed: February 27, 2004
    Date of Patent: May 4, 2010
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Todd A. Thompson, George Wilding
  • Chroman-Derived Anti-Androgens For Treatment of Androgen-Mediated Disorders
    Publication number: 20100056619
    Abstract: Methods for the prevention and/or alleviation of androgen-mediated disorders by administering a chroman-derived anti-androgen compound are provided by the present invention. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived anti-androgen compounds useful in the prevention and/or alleviation of androgen-mediated disorders, particularly prostate cancer.
    Type: Application
    Filed: October 19, 2009
    Publication date: March 4, 2010
    Inventors: Todd A. Thompson, George Wilding
  • Chroman-Derived Compounds For The Treatment Of Cancer
    Publication number: 20090326055
    Abstract: The present invention provides methods for inhibiting the growth of androgen-independent prostate cancer tumor cells in a human comprising administering to the human. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived compounds useful in the alleviation of cancer.
    Type: Application
    Filed: May 29, 2008
    Publication date: December 31, 2009
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Todd A. Thompson, George Wilding
  • N1,N4-bis(buta-1,3-dienyl)butane-1,4-diamine pharmaceutical compositions and methods thereof
    Publication number: 20080114072
    Abstract: N1,N4-bis(buta-1,3-dienyl)butane-1,4-diamine dihydrochloride (also referred to as MDL 72,527 and N,N?-di-2,3-butadienyl-1,4-butanediamine dihydrochloride), or salts or solvates thereof, its use as an antioxidant, its use in preventing and/or treating prostate cancer in male humans, and its use in reducing the concentration of reactive oxygen species in human prostate gland tissue or any other body tissue, and methods of making the compound thereof. Other methods include inhibiting acetyl polyamine oxidase in human prostate tissue or other human body tissue comprising administering a therapeutic amount of N,N?-bis(2,3-butadienyl)-1,4-butanediamine or a salt or solvate thereof to the human, and a method of determining oxidative stress in human prostate tissue or other human or animal body tissue comprising measuring a ratio of oxidized 2?,7?-dichlorodihydrofluorescein diacetate fluorescence:DNA fluorescence and hydroethidine dye fluorescence ex vivo or in vivo.
    Type: Application
    Filed: May 3, 2007
    Publication date: May 15, 2008
    Inventors: Hirak S. Basu, Dawn R. Church, Patrick M. Woster, George Wilding
  • Chroman-derived anti-androgens for treatment of androgen-mediated disorders
    Publication number: 20050192342
    Abstract: Methods for the prevention and/or alleviation of androgen-mediated disorders treatable by administering a chroman-derived anti-androgen compound are provided by the present invention. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived anti-androgen compounds useful in the prevention and/or alleviation of androgen-mediated disorders, particularly prostate cancer.
    Type: Application
    Filed: February 27, 2004
    Publication date: September 1, 2005
    Inventors: Todd Thompson, George Wilding